SCHEMBL5558418

SCHEMBL5558418

CCOC(=O)c1cccc(N=C=S)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 1/20 0.49
CYP4A11 Q02928 1/20 0.49
NPC1 O15118 3/20 0.47
RAB9A P51151 3/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2C9 P11712 1/20 0.47
HPGD P15428 1/20 0.47
CYP2C19 P33261 1/20 0.47
CA12 O43570 1/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
CA7 P43166 1/20 0.46
CA9 Q16790 1/20 0.46
CA14 Q9ULX7 1/20 0.46
KMT2A Q03164 2/20 0.46
MEN1 O00255 1/20 0.46
MAPT P10636 1/20 0.46
ALDH1A1 P00352 1/20 0.46
TSHR P16473 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30427003 0.87 CYP4F2 (0.50) CYP4F2CYP4A11NPC1RAB9ASMN1; SMN2
SCHEMBL445504 0.87 CYP4F2 (0.50) CYP4F2CYP4A11NPC1RAB9ASMN1; SMN2
SCHEMBL7393239 0.84 CA12 (0.51) NPC1RAB9ACYP1A2CYP2C9CYP2C19
SCHEMBL29754225 0.83 ALDH1A1 (0.48) CYP4F2CYP4A11NPC1RAB9ASMN1; SMN2
SCHEMBL1421363 0.83 ALDH1A1 (0.48) CYP4F2CYP4A11NPC1RAB9ASMN1; SMN2
SCHEMBL23191916 0.82 TDP1 (0.58) NPC1RAB9ASMN1; SMN2CYP2C9HPGD
SCHEMBL1457515 0.81 MAPT (0.56) NPC1RAB9ASMN1; SMN2CYP1A2HPGD
SCHEMBL14257225 0.81 CYP4F2 (0.54) CYP4F2CYP4A11NPC1RAB9ASMN1; SMN2
SCHEMBL6070567 0.80 MAPT (0.58) CYP4F2CYP4A11NPC1RAB9ASMN1; SMN2
SCHEMBL12644215 0.80 CYP4F2 (0.52) CYP4F2CYP4A11NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070197577-A1 Inhibitors of anthrax lethal factor CENGENT THERAPEUTICS (US) 2007-08-23 US disclosed
WO-2005027856-A2 INHIBITORS OF ANTHRAX LETHAL FACTOR CENGENT THERAPEUTICS (US) 2005-03-31 WO disclosed
EP-0117511-B1 SILVER HALIDE COLOR PHOTOGRAPHIC LIGHT-SENSITIVE MATERIAL FUJI PHOTO FILM CO., LTD. (JP) 1989-09-20 EP disclosed
US-4737452-A WITH AROMATIC COMPOUND CONTAINING MERCAPTO AND HYDROZIDE GROUPS FUJI PHOTO FILM CO., LTD. (JP) 1988-04-12 US disclosed
US-4628024-A RELEASING A FOGGING AGENT; CONTRAST; STORAGE STABILITY FUJI PHOTO FILM CO., LTD. (JP) 1986-12-09 US disclosed
US-4550070-A Direct positive silver halide photographic light-sensitive materials FUJI PHOTO FILM CO., LTD. (JP) 1985-10-29 US disclosed
EP-0154293-A2 Silver halide photographic materials FUJI PHOTO FILM CO., LTD. (JP) 1985-09-11 EP disclosed
EP-0147765-A2 Silver halide photographic light-sensitive material FUJI PHOTO FILM CO., LTD. (JP) 1985-07-10 EP disclosed
EP-0117511-A2 Silver halide color photographic light-sensitive material FUJI PHOTO FILM CO., LTD. (JP) 1984-09-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197577-A1 Inhibitors of anthrax lethal factor APAF1, ANTXR2, LITAF CYP4F2 1720/4885CYP4A11 3265/4885NPC1 1839/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.